MGCD0103

MGCD0103 is a benzamide histone deacetylase inhibitor that is currently under investigation for its potential use in the treatment of various types of cancer. It is being developed by MethylGene Inc., a biopharmaceutical company based in Montreal, Canada.

Mechanism of Action

MGCD0103 inhibits histone deacetylase, an enzyme that is involved in the regulation of gene expression. By inhibiting this enzyme, MGCD0103 can alter the expression of genes that control cell growth and differentiation, potentially slowing or stopping the growth of cancer cells.

Clinical Trials

MGCD0103 has been tested in several clinical trials for various types of cancer, including non-Hodgkin's lymphoma, Hodgkin's lymphoma, leukemia, and solid tumors. The results of these trials have been mixed, with some showing promise and others showing little to no effect.

Side Effects

Like all chemotherapy drugs, MGCD0103 has the potential to cause side effects. These can include nausea, vomiting, diarrhea, fatigue, and anemia. More serious side effects can include liver damage and heart problems.

Future Research

While MGCD0103 has shown promise in some clinical trials, more research is needed to determine its efficacy and safety. Future research will likely focus on identifying the types of cancer that are most responsive to MGCD0103, as well as optimizing the dosing and administration of the drug.

This chemistry-medicine related article is a stub. You can help WikiMD by expanding it.